Skip to main content
NewslettersWatchlist

Kura Oncology(KURA-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low9.68
Day High12.24
Open:11.80
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Newswire.ca
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
GlobeNewswire
Kura Oncology Reports Third Quarter 2024 Financial Results
GlobeNewswire
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
GlobeNewswire
Kura Oncology to Report Third Quarter 2024ย Financial Results
GlobeNewswire
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
GlobeNewswire
Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors
GlobeNewswire
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
Motley Fool
2 Incredible Growth Stocks to Buy Hand Over Fist
The Globe and Mail
U.S. equities in the spotlight for price trend enthusiasts
Barchart
Kura Oncology (KURA) Offers Speculators a Profit-Scalping Opportunity
MarketBeat
7 Best Cancer Stocks to Invest in Now
Barchart
Stock Index Futures Move Higher as Investors Await Fed Rate Decision, U.S. PPI Data
Globe Newswire
Kura Oncology Reports Second Quarter 2022 Financial Results
Globe Newswire
Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference
Globe Newswire
Kura Oncology to Report Second Quarter 2022 Financial Results
Globe Newswire
Kura Oncology to Participate in Three Upcoming Investor Conferences
Globe Newswire
Kura Oncology Reports First Quarter 2022 Financial Results
Globe Newswire
Kura Oncology to Report First Quarter 2022 Financial Results
Globe Newswire
Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer
Globe Newswire
Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting
Globe Newswire
Kura Oncology to Participate in Two Upcoming Investor Conferences
Globe Newswire
Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results

Profile

Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright ยฉ 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright ยฉ 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.